GlassScriptPhysician profile
Faraz Sandhu
NPI 1245385947
$5,764.97
in general payments reported to CMS, 2019-2025
26 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $815 · 2021: $738 · 2022: $843 · 2023: $660 · 2024: $875 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,158.99 | 2019-2025 | Impella |
| Cardiovascular Systems INC. | $710.69 | 2019-2023 | Diamondback Coronary |
| Endologix LLC | $705.70 | 2022-2024 | Ovation Ix Iliac Stent Graft, Alto Abdominal Stent Graft System |
| Medtronic, INC. | $607.32 | 2021-2025 | Symplicity G3, Endurant Iis, Abre |
| Bard Peripheral Vascular, INC. | $503.48 | 2020-2023 | |
| Medtronic Vascular, INC. | $317.97 | 2019-2020 | |
| Boston Scientific Corporation | $274.43 | 2019-2024 | Ranger |
| Philips North America LLC | $238.67 | 2019-2024 | (5091) Amb Mon & Diag Und |
| Abbott Laboratories | $222.85 | 2023-2025 | Esprit, Diamondback Peripheral, Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $163.91 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.80 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $156.47 | 2019-2023 | Farxiga |
| Penumbra, INC. | $100.06 | 2019-2022 | |
| Terumo Medical Corporation | $79.53 | 2019-2023 | Tr Band |
| Shockwave Medical, INC | $63.19 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $55.49 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ekos Corporation | $54.05 | 2019 | |
| Angiodynamics, INC. | $29.24 | 2020-2023 | Alphavac |
| Janssen Pharmaceuticals, INC | $28.24 | 2022 | |
| Pfizer INC. | $28.04 | 2023 | |
| Amgen INC. | $27.61 | 2023 | Repatha |
| W. L. Gore & Associates, INC. | $18.40 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Cvrx, INC. | $16.93 | 2023 | Barostim Neo System |
| Cardinal Health 200 LLC | $16.01 | 2021 | |
| Cook Medical LLC | $13.45 | 2023 | Zilver Ptx |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraz Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.